Biocompare highlights Abselion among industry voices shaping mAb characterization
In Biocompare’s editorial The Evolving Landscape of mAb Characterization, leaders from across the biologics field — including Abselion CEO Dr Ruizhi Wang — discuss how emerging analytical platforms are redefining speed, reliability, and accessibility in antibody analysis.
Through the Amperia™ platform, Abselion is enabling scientists to quantify antibodies directly and reproducibly, supporting faster decisions across research and development.
Read the article here.